[1] |
Rendon A,Schakel K.Psoriasis Pathogenesis and Treatment[J].Int J Mol Sci,2019,20(6):1475.
|
[8] |
Lowes MA,Suárez-Farinas M,Krueger JG.Imm unology of psoriasis[J].Annu Rev Immunol,2014,32:227-255.
|
[14] |
肖芳,郑成云,蒋卫东.NETs 在自身免疫性疾病发病机制中的作用研究进展[J].中国免疫学杂志,2017,33(5):781-783,787.
|
[16] |
李贝金,李潇,薛嘉睿,等.新冠肺炎炎症风暴的机制探讨及中医药的干预作用[J].中国实验方剂学杂志,2020,26(13):32-38.
|
[23] |
Visconti B,Paolino G,Carotti S,et al.Immunohistochemical expression of VDR is associated with reduced integrity of tight junction complex in psoriatic skin[J].J Eur Acad Dermatol Venereol,2015,29(10):2038-2042.
|
[24] |
Wang W,Shu GF,Lu KJ,et al.Flexible liposomal gel dualloaded with all-trans retinoic acid and betamethasone for enhanced therapeutic efficiency of psoriasis[J].J Nanobiotechnology,2020,18(1):80.
|
[25] |
Banerjee S,Biehl A,Gadina M,et al.JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases:Current and Future Prospects[J].Drugs,2017,77(5):521-546.
|
[26] |
Papp K,Gordon K,Thaci D,et al.Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis[J].N Engl J Med,2018,379(14):1313-1321.
|
[27] |
Li H,Zuo J,Tang W.Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases[J].Front Pharmacol,2018,9:1048.
|
[28] |
朱愿超,孙雪林,胡欣.银屑病治疗靶向药物的研究进展[J].中国药房,2019,30(4):542-547.
|
[29] |
Siiskonen H,Harvima I.Mast Cells and Sensory Nerves Contribute to Neurogenic Inflammation and Pruritus in Chronic Skin Inflammation[J].Front Cell Neurosci,2019,13:422.
|
[30] |
Jin J,Xue N,Liu Y,et al.A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models[J].Acta Pharm Sin B,2020,10(2):276-288.
|
[31] |
Maceyka M,Spiegel S.Sphingolipid metabolites in inflammatory disease[J].Nature,2014,510(7503):58-67.
|
[32] |
Mylonas A,Conrad C.Psoriasis:Classical vs.Paradoxical.The Yin-Yang of TNF and Type I Interferon[J].Front Immunol,2018,9:2746.
|
[33] |
戴华拓,任韵清.生物制剂治疗银屑病的药物遗传学研究进展[J].中国麻风皮肤病杂志,2019,35(11):696-700.
|
[34] |
Hawkes JE,Yan BY,Chan TC,et al.Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis[J].J Immunol,2018,201(6):1605-1613.
|
[35] |
Hawkes JE,Chan TC,Krueger JG.Psoriasis pathogenesis and the development of novel targeted immune therapies[J].J Allergy Clin Immunol,2017,140(3):645-653.
|
[2] |
Mahil SK,Capon F,Barker JN.Update on psoriasis immunopathogenesis and targeted immunotherapy[J].Semin Immunopathol,2016,38(1):11-27.
|
[3] |
Lande R,Gregorio J,Facchinetti V,et al.Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide[J].Nature,2007,449(7162):564-569.
|
[4] |
Duvallet E,Semerano L,Assier E,et al.Interleukin-23:a key cytokine in inflammatory diseases[J].Ann Med,2011,43(7):503-511.
|
[5] |
Ganguly D,Haak S,Sisirak V,et al.The role of dendritic cells in autoimmunity[J].Nat Rev Immunol,2013,13(8):566-577.
|
[6] |
Arakawa A,Siewert K,Stohr J,et al.Melanocyte antigen triggers autoimmunity in human psoriasis[J].J Exp Med,2015,212(13):2203-2212.
|
[7] |
Di Cesare A,Di Meglio P,Nestle FO.The IL-23/Th17 axis in the immunopathogenesis of psoriasis[J].J Invest Dermatol,2009,129(6):1339-1350.
|
[9] |
Johnson-Huang LM,Suárez-Farinas M,Pierson KC,et al.A single intradermal injection of IFN-γ induces an inflammatory state in both non-lesional psoriatic and healthy skin[J].J Invest Dermatol,2012,132(4):1177-1187.
|
[10] |
Madonna S,Scarponi C,Sestito R,et al.The IFN-gammadependent suppressor of cytokine signaling 1 promoter activity is positively regulated by IFN regulatory factor-1 and Sp1 but repressed by growth factor independence-1b and Krüppel-like factor-4,and it is dysregulated in psoriatic keratinocytes[J].J Immunol,2010,185(4):2467-2481.
|
[11] |
Abdallah MA,Abdel-Hamid MF,Kotb AM,et al.Serum interferon -gamma is a psoriasis severity and prognostic marker[J].Cutis,2009,84(3):163-168.
|
[12] |
Deng Y,Chang C,Lu Q.The Inflammatory Response in Psoriasis:a Comprehensive Review[J].Clin Rev Allergy Immunol,2016,50(3):377-389.
|
[13] |
Shiga T,Sato K,Kataoka S,et al.TNF inhibitors directly target Th17 cells via attenuation of autonomous TNF/TNFR2 signalling in psoriasis[J].J Dermatol Sci,2015,77(1):79-81.
|
[15] |
Chousterman BG,Swirski FK,Weber GF.Cytokine storm and sepsis disease pathogenesis[J].Semin Immunopathol,2017,39(5):517-528.
|
[17] |
Mrowietz U,Kragballe K,Reich K,et al.Definition of treatment goals for moderate to severe psoriasis:a European consensus[J].Arch Dermatol Res,2011,303(1):1-10.
|
[18] |
Menter A.Psoriasis and psoriatic arthritis overview[J].Am J Manag Care,2016,22(8 Suppl):s216-s224.
|
[19] |
Chong M,Fonacier L.Treatment of Eczema:Corticosteroids and Beyond[J].Clin Rev Allergy Immunol,2016,51(3):249-262.
|
[20] |
Smith CH,Barker JN.Psoriasis and its management[J].BMJ,2006,333(7564):380-384.
|
[21] |
Sevilla LM,Pé rez P.Glucocorticoids and Glucocorticoid-Induced-Leucine-Zipper(GILZ)in Psoriasis[J].Front Immunol,2019,10:2220.
|
[22] |
Li J,Sun L,Sun J,et al.Pooling analysis regarding the impact of human vitamin D receptor variants on the odds of psoriasis[J].BMC Med Genet,2019,20(1):161.
|